Trips
Trips
The General Agreement on Tariffs and Trade (GATT) was the only
multilateral mechanism overseeing international commerce until the World
Trade Organization (WTO) was established in 1995. Under GATT, there were
eight rounds of negotiations, the first five of which were solely focused on
tariffs, while the sixth round included discussions on anti-dumping
measures, which included provisions for member nations to control the
dumping of goods into their territory by other nations that could harm their
economies.
The Uruguay Round was the last GATT round (1986-1994). It was in this
session that the first discussions on trade linked to agriculture, services, and
intellectual property rights were conducted. All 123 countries that took part
in the Uruguay Round, including India, became members of the WTO. WTO
now has 164 members, accounting for about 90% of the world’s countries.
The World Trade Organization (WTO) is in charge of negotiating and
implementing new international trade agreements. It is also responsible for
ensuring that the majority of the world’s trading nations comply with the
trade agreements they have signed. The WTO is the legal and administrative
framework for managing and growing international trade connections
between its 157 members on a multilateral basis. Its goal is to establish fair
and secure international trading arrangements in order to stimulate trade
and investment and raise global living standards.
The TRIPS Agreement is one of the most significant WTO accords. The
Agreement went into effect on January 1, 1995.
What is the TRIPS Agreement about?
all of which outline the procedures and remedies that must be provided
so that the right holders can successfully exercise their rights.
Part II- This part covers the requirements for the availability, scope, and
application of intellectual property rights. (Article 9 to Article 40)
Part III- The enforcement of IPRs is the focus of this part. (Article 41 to
Article 61)
Part IV: This part covers the procedures for obtaining and maintaining
intellectual property rights. (Article 62)
Part V: This part deals with the prevention and resolution of conflicts
resulting from the provisions of the Agreement. (Article 63 to Article 64)
Part VI: This part is about transitional agreements. (Article 65 to Article 67)
Part VII: This part of the Agreement deals with a variety of institutional
arrangements. (Article 68 to Article 73)
Trademarks
Article 15 states that any sign, or set of signs, able to distinguish one
undertaking’s products and services from other undertakings’, shall be
eligible for trademark registration, provided that it is clearly detectable. Such
signs, in particular words, characters, digits, figurative components, and
colour combinations, as well as any combination of these signs, must be
acceptable for trademark registration.
According to Article 16, the trademark owner has the exclusive right to
restrict third parties from using similar or identical signs for products or
services that are similar to those for which the trademark is registered.
Geographical indications
As per Article 22, geographical indications designate a good as coming from
a member’s territory, or an area or place within that territory, where the
good’s quality, reputation, or other attribute is largely due to its
geographical origin. Traditionally, some commercial items have been
manufactured in a geographically defined territory. In commercial relations,
the geographical indicator becomes the dependable “carrier” of qualifying
product features when these items are accredited to certain criteria
fundamentally due to their geographical provenance. The purpose and value
of geographical indications are subsequently given to trademarks, and they
are entitled to legal protection.
Industrial designs
Articles 25 and 26 of the agreement says members must ensure that fresh
or unique industrial designs generated independently are protected. The
Agreement, which is based on the Paris Convention but goes much beyond
it, promises to preserve industrial designs for a minimum of 10 years. When
such activities are conducted for commercial objectives, the right holder can
ban third parties who do not have the holder’s agreement from producing,
importing or selling items that incorporate the protected design.
Patents
Members may also exclude diagnostic, medicinal, and surgical procedures for
the treatment of people and animals from patentability.
The length of protection is normally 20 years from the date of filing of the
patent application. Member nations could provide specific exemptions to
exclusive rights conferred by a patent under Article 21 of the Agreement,
given that such exclusions do not unreasonably conflict with a normal
exploitation of the patent and therefore do not unreasonably bias the patent
owner’s legitimate interests, taking into consideration the legitimate
interests of third parties. Furthermore, Article 29 mandates that the patent
filing discloses the innovation in a manner that is explicitly clear and
complete for a person knowledgeable in the art to carry out the invention.
Article 31 of the Agreement contains provisions that allow the government of
a member nation to award a compulsory licence for medicines without the
patentee’s approval, subject to specific circumstances.
Enforcement
Transitional agreements
Institutional arrangements
Article 68 of the TRIPS Agreement establishes The TRIPS Council. The TRIPS
Council oversees the administration of this Agreement, including members’
compliance with their duties under it, and provides members with the
opportunity to consult on trade-related aspects of intellectual property
rights. It carries out any other obligations that the members delegate to it,
including providing any help sought by them in the context of dispute
resolution procedures. The TRIPS Council may consult with and obtain
information from any source it finds relevant in carrying out its tasks.
Conclusion
India became an associate of the WTO and thus a participant in the TRIPS
Agreement in 1995. Before the adoption of TRIPS, India had a well-
established intellectual property outline with its laws, such as the Patents
Act, Copyright Act, and Trademarks Act and the TRIPS Agreement presented
certain changes and obligations that required India to modify its prevailing
intellectual property laws to comply with the international values set by the
agreement.
India has made efforts to comply with TRIPS obligations while also utilizing
gives to safeguard public health and encourage access to affordable
medicines. India continues to navigate the difficulties of intellectual property
protection, seeking constancy between innovation, public health, and
traditional knowledge preservation. Member states are grateful to create
applicable national laws to implement the requirements of the TRIPS.
Importance of TRIPS
All WTO member countries are required to offer protection under TRIPS that
is of a similar level and also gives an agenda for the enforcement of the
intellectual property rights act as an assurance that innovators, creators,
and inventors obtain the protection & incentives they require to progress
their concepts and inventions, the TRIPS Agreement is of great importance.
This promotes more innovation which results in a rise in the economy and
the formation of many new jobs, the legal framework for the implementation
of intellectual property rights is given by TRIPS too, serving in the protection
of innovators, creators, and inventors from the unlawful use of their
creations as this helps to fight in contradiction of piracy and counterfeiting
and this helps to safeguard the rights of innovators and promote additional
innovation. The TRIPS agreement helps to ensure a free and reasonable
international trading system by giving all members of WTO an even playing
arena in terms of intellectual property rights.
One unique aspect of the TRIPS Agreement in India is its utilization of the
"mailbox" provision for patent applications related to pharmaceuticals as this
provision allowed India to accede to the examination and granting of product
patents for pharmaceuticals until 2005, even nevertheless the TRIPS
Agreement required immediate acquiescence.
The Bayer case involves a patent dispute regarding the pharmaceutical drug
Sorafenib Tosylate, marketed under the product Nexavar, used to treat
kidney and liver cancers. Bayer Corporation had obtained a patent for the
drug in India and therefore, Natco Pharma, an Indian generic pharmaceutical
company, filed an application seeking a compulsory license to manufacture
and sell a generic version of Nexavar, citing high prices and limited access.
Issue:
The main issue was whether Natco Pharma should be decided a compulsory
license, allowing them to produce and sell a generic version of Nexavar
without the consent of the patent holder, Bayer Corporation and this raised
interrogations about access to affordable medicines, balancing patent rights,
and addressing public health concerns.
Decision:
Impact:
The case highlighted India's commitment to utilizing gives within the TRIPS
Agreement, such as compulsory licensing, to safeguard access to essential
medicines for its population. It also underscored India's exertions to address
public health concerns, particularly in cases where patented drugs are priced
out of reach for numerous patients. The Bayer case contributed to the
constant dialogue surrounding intellectual property rights, access to
medicines, and the balance between innovation and public health in India.